TY - JOUR
T1 - Colon cancer, version 1.2017
T2 - Clinical practice guidelines in oncology
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Cederquist, Lynette
AU - Chan, Emily
AU - Chen, Yi Jen
AU - Cooper, Harry S.
AU - Deming, Dustin
AU - Engstrom, Paul F.
AU - Enzinger, Peter C.
AU - Fichera, Alessandro
AU - Grem, Jean L.
AU - Grothey, Axel
AU - Hochster, Howard S.
AU - Hoffe, Sarah
AU - Hunt, Steven
AU - Kamel, Ahmed
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Messersmith, Wells A.
AU - Mulcahy, Mary F.
AU - Murphy, James D.
AU - Nurkin, Steven
AU - Saltz, Leonard
AU - Sharma, Sunil
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stoffel, Elena M.
AU - Stotsky-Himelfarb, Eden
AU - Willett, Christopher G.
AU - Wu, Christina S.
AU - Gregory, Kristina M.
AU - Freedman-Cass, Deborah
N1 - Publisher Copyright:
© 2017 National Comprehensive Cancer Network, Inc. All rights reserved.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.
AB - This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.
UR - http://www.scopus.com/inward/record.url?scp=85016215716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016215716&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2017.0036
DO - 10.6004/jnccn.2017.0036
M3 - Review article
C2 - 28275037
AN - SCOPUS:85016215716
SN - 1540-1405
VL - 15
SP - 370
EP - 398
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 3
ER -